

Gipuzkoa, growth path to become a world reference in Advanced Therapies.

The main objective of the project is becoming a scientific-technological landmark in the emerging Advanced Therapies sector. This is a clear example of an efficient public-private collaboration project.

To achieve this objective, it is key to define the segment of advanced therapies to develop, in order to find a niche where the region can be competitive. For that purpose, good practices and international experiences will be identified and defined, as well as actors and roles to be played in the strategy. On one hand, the region hosts two CDMOs of international reputation, Viralgen and ViveBiotech, which could serve as basis for the creation of an industrial value chain in the territory. On the other hand, the Basque Country has one of the best public health services in the world playing a key role in conducting pre-clinical and clinical trials of these therapies in collaboration with the pharmaceutical industry and other institutions such as CIMA (Centro de Investigación Médica Aplicada de la Universidad de Navarra). Another part to take into account for the design of the strategy, is creating and attracting talent. To this end, a specialised education plan in the advanced therapies sector will be designed. Once this stage has been completed, a short-, medium- and long-term strategy will be designed for the development of the territory, together with a scheme for financing and implementing the strategy. All this will allow Gipuzkoa to become a world reference point in the development of Advanced Therapies.

Moderator:

- **Angel Sánchez. SILO**

Speakers:

- **Iker Estensoro (Diputación Foral de Gipuzkoa)**
- **Javier García-Cogorro (Viralgen, CEO)**
- **Gurutz Linazasoro (VIVEbiotech, CEO)**
- **Gloria Gonzalez-Aseguinolaza (CIMA-Universidad de Navarra, Deputy Director)**